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Infections caused by emerging Cryptococcus non-neoformans species are being reported
with  increasingly frequency. Here, we present a case of fungaemia by Cryptococcus lau-
rentii in a woman receiving aggressive immunosuppressive therapy for cervical neoplasia.
Three venous blood samples were aseptically collected on consecutive days and C. lauren-
tii  was isolated and identiﬁed through phenotypic and molecular methods. After central
venous catheter removal and appropriate antifungal therapy, the patient showed signiﬁcant
improvement and blood culture became negative. Thus, patients following immunosup-Fungaemia
Cancer
pressive therapies and using invasive medical devices are at risk of C. laurentii blood
infections.
©  2015 Elsevier Editora Ltda. All rights reserved.
Cryptococcus laurentii generally cause superﬁcial to deepIntroduction
Cervical cancer is an important malignancy condition world-
wide, with a signiﬁcant mortality rate in developing countries,
which corresponds to annual incidence of approximately
132,000 cases. According to the Brazilian National Cancer
Institute (INCA), there are 18,430 newly reported cases per year
and this cancer is the fourth leading cause of death in female
population represented by 4800 cases with fatal outcome.
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cancer had led to an increasing number of severe opportunis-
tic fungal infections such as cryptococcosis.1 Commonly, it is
caused by Cryptococcus neoformans and Cryptococcus gattii, with
recent reports by non-neoformans Cryptococcus species as C.
laurentii which is a basidiomycetous encapsulated yeast, also
found in the droppings and cloacal samples of pigeons.2nida Professor Nelson Chaves, s/n, Cidade Universitária, 50670-420
seated infections in immunosuppressed patients. The fun-
gal infection may be acquired by inhalation leading to






















































Fig. 1 – Budding encapsulated spherical and ellipsoidal
yeast cells of Cryptococcus laurentii from blood specimen atb r a z j i n f e c t d i s .
symptomatic pulmonary infection or through the use of
ontaminated invasive medical devices. Also, other risk fac-
ors include: prior steroid and immunosuppressant exposure,
zoles prophylaxis, low CD4 count, and neutropenia.2
ase  report
he procedures described herein are in accordance with ethi-
al standards of the Ethics Committee on researches involving
umans from the Universidade Federal de Pernambuco/Brazil.
A 42-year-old Brazilian woman was admitted in Decem-
er 2012 to the Hospital das Clínicas, a public tertiary hospital
ocated in Recife, Brazil. She had had fever for one week and
iffuse abdominal pain and discomfort during intercourse. A
omplete blood count revealed no abnormalities and blood
nd urine cultures were also negative for bacteria and fungi in
his occasion. Colposcopy procedures exhibited an abnormal
rea in the cervix, and the Papanicolaou test showed abnormal
ells. Cervical colposcopic biopsies, endocervical curettage
nd cone biopsy diagnosed cervical intraepithelial neoplasia (CIN)
rade 3 (squamous cell carcinoma). Chemotherapy and radio-
herapy elicited good responses and ultimately a full clinical
ecovery. Subsequently the patient was discharged home.
However, one year thereafter the patient was hospitalized
ith diabetes mellitus, abdominal distension, appetite loss,
ypoalbuminemia, and intestinal sub occlusion, characteristic
f an actinic stenosis. Bowel resection and jejunostomy were
equired to correct the intestinal stenosis, with concomitant
dministration of parenteral nutrition and antibiotic therapy.
In January 2014, due to adhesions between bowel loops
ssociated with stenosis and presence of mucous ﬁs-
ula, another corrective enterectomy was performed which
evealed the presence of fecal content, intestinal evisceration
nd aponeurotic dehiscence. Postoperatively, a surgical wound
nfection caused by Pseudomonas aeruginosa,  Citrobacter sp. and
cinetobacter sp., aggravated by sepsis and a generally wors-
ning clinical condition required long-term antibiotic therapy
nvolving intravenous vancomycin, followed by imipenem and
etronidazole. However, three months later she was readmit-
ed to the intensive care unit presenting fever episodes, severe
bdominal pain, weakness and respiratory distress. Labo-
atory investigations showed elevated urea (207 mg/dl) and
reatinine (4.0 mg/dl) levels, leukopenia (WBC 3.60 × 103/l),
ow hemoglobin (8.0 g/dl) and platelets (8500/l)  levels.
Duplicate venous blood samples were aseptically collected
nto VACUTAINER® tubes using EDTA anticoagulant and blood
ultures (BACTEC 860 system; Becton Dickinson, Inc., Sparks,
D)  on three consecutive days. Samples were processed by
tandard methods (direct examination and culture) for myco-
ogical diagnosis at the Medical Mycology Laboratory, Federal
niversity of Pernambuco. Direct examination was performed
ith and without India ink. Collected material was cultured on
abouraud Dextrose Agar medium (Difco Laboratories) supple-
ented with chloramphenicol, incubated at 25 ◦C and 37 ◦C
n an aerobic atmosphere for 10 days. The taxonomic iden-
iﬁcation was carried out with pure cultures and also using
olecular techniques by comparing D1/D2 sequences of the
solated yeast strains with the type strain CBS 139/Genbank
F075469.3direct examination and contrasted with India ink.
Budding capsulated yeast cells were visualized directly in
wet ﬁlms with contrast microscopy (India ink) and all blood
cultures were positive after ﬁve days of growth (Fig. 1). Macro-
scopically, 50–100 white-cream colonies grew, with mucoid to
butyrous consistence, which darkened with age. The reverse
was colorless. Microscopically, contrasted budding encapsu-
lated spherical and ellipsoidal yeast cells of approximately
5 m in diameter were observed, which was morphologically
consistent with their identiﬁcation as Cryptococcus species.
Nonfermentative colonies, absence of KNO3 utiliza-
tion, caffeic acid negative, and urease positive reactions
were observed through standard identiﬁcation techniques.
The assimilation proﬁle showed utilization of lactose, d-
glucuronate, d-gluconate, and melibiose, which indicates C.
laurentii as the agent of the bloodstream infection. The iden-
tiﬁcation of the microorganism was also conﬁrmed using
molecular techniques.
In addition, bronchoalveolar lavage and cerebrospinal ﬂuid
were analyzed through direct exam, culture, and cryptococcal
latex agglutination. However, no fungi were detected.
The minimal inhibitory concentrations (MICs) of the etio-
logical agent isolated from blood samples against ﬂuconazole
and amphotericin B were determined using the broth micro-
dilution method according to the M27-A3 document from
the Clinical and Laboratories Standards Institute-CLSI.4 The
isolates were sensitive to amphotericin B (1.0 g/ml) and ﬂu-
conazole (4 g/ml).
Due to persistent elevated levels of urea and creatinine, ﬂu-
conazole was the drug of choice and the patient was treated
intravenously (400 mg)  for 22 weeks. After central venous
catheter removal she showed signiﬁcant improvement and
was discharged home.
DiscussionIn the case herein described a woman with an underlying
malignancy was severely immunocompromised due to the
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Table 1 – Reported cases of Cryptococcus laurentii fungaemia in humans.
Year/Reference Age/Sex Underlying conditions Treatment Outcome
1995/6 Non-informed Acute myelogenous leukemia Itraconazole Resolved
1995/6 Non-informed Acute myelogenous leukemia Ketoconazole Resolved
1997/7 17/M Neutropenia (bone marrow
transplantation)
Fluconazole Resolved
1997/8 27d/M Premature birth Amphotericin B, ﬂucytosine Resolved
1997/8 27/F Bacterial endocarditis (catheter
use)
Fluconazole Resolved
1998/9 26/M Solid tumor Fluconazole Resolved
1998/9 50/M Non-Hodgkin’s lymphoma Amphotericin B Fatal
1999/9 57/M Acute myelogenous leukemia Amphotericin B Resolved
2000/10 74d/F Premature birth Amphotericin B Resolved
2002/11 Non-informed Solid tumor Amphotericin B Resolved
2009/12 39/M Glomerulonephritis on
immunosuppressive therapy
Itraconazole Resolved
2013/2 76/M Cardiovascular disease Amphotericin B/Fluconazole Resolved
2015/(present report) 42/F Cervical neoplasia Fluconazole Resolved
rM, male; F, female; d, days.
immunosuppressive effects of radio and chemotherapy cycles
and due to her long-standing diabetic status. Additionally,
the patient had a predisposition due to the use of multiple
catheters and invasive medical devices, which were consid-
ered the possible source of fungaemia, although catheters
cultures were not evaluated during hospitalization.
Cryptococcus commonly invades the human body after
inhalation, through the alimentary tract or injured skin. From
the portal of entry, the encapsulated yeast cells are eas-
ily transported via bloodstream to other parts of the body.
The presence of invasive devices is considered a signiﬁcant
risk factor associated with C. laurentii infections.2,5 In our
case, the catheter tip was only removed during the anti-
fungal treatment and has not been sent for microbiological
analysis.
Furthermore, what makes this case relevant is the fact that
fungaemia was caused by a rather uncommon microorganism,
C. laurentii, for which there is still a paucity of data in the lit-
erature. For instance, there are few published cases for both
superﬁcial and deep-seated infections, including fungaemia
(Table 1).
A review of the medical literature indicated that this report
represents the ﬁrst isolation of C. laurentii from the blood of
a patient with cervical neoplasia under radio and chemother-
apy. A systematic review by Khawcharoenporn et al.5 showed
that non-neoformans and non-gattii cryptococcal infections
occur sporadically, with C. neoformans and Cryptococcus albidus
accounting for 80% of the reported cases.
Due to the rarity of cases involving C. laurentii, a standard
treatment has not yet been established. Commonly, ampho-
tericin B with ﬂucytosine is recommended. However, azole
derivatives have been used successfully in some cases5 as
veriﬁed in the present case.
Susceptible patients, especially those at risk due to
immunosuppressive therapies, might inadvertently come into
contact with such species and develop nosocomial infec-
tions. Interestingly, it appears that C. laurentii, a non-C.
neoformans species, has managed to expand beyond its nor-
mal  environmental niche to become a recognized human
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